Loading…
← CockpitCompetitor Analysis › 476830.KS Rznomics Inc.Open in the cockpit ↗

Rznomics Inc.476830.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum laggard 4
Mkt cap
$418M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$3.67M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-155.3 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · KRW₩18,800
1D+1.8%
1W-11.5%
1M-19.7%
3M-46.7%
6M-75.7%
YTD-76.6%
1Yn/a
ATR %9.9%
52w lowhigh84.7% off high

What Rznomics does

No business profile yet.

Rznomics at a glance

Size Rznomics (476830.KS) is a South Korea Health Care company (Biotechnology) with a market value of $418M, the 392nd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩18,800 on 18 Nov 2026.

Performance Over six months the shares fell 75.7%, against -22.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 65.4% over the last twelve months (peer median +4.8%); the operating margin is -1,111.6% (peer median -4.5%).

Valuation It trades at 215.1× enterprise value to sales against a peer median of 4.0× (2nd most expensive of 16).

Capital Return on invested capital runs 155.3 points below its cost of capital (5.6% WACC).

Relative performance

25507510021 May 202621 Aug 202618 Nov 2026Peer median 78476830.KS 25
Six months, rebased to 100: Rznomics against the median of its 20 peers (local-currency closes).

Rznomics financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩2.45B₩7.92B₩0₩144M₩0
Revenue growth——-100%——
Gross profitn/an/a-₩1.08B-₩812M-₩703M
EBITDA-₩26.1B-₩13.6B-₩11.8B-₩14.6B-₩18.5B
Net income-₩25.9B-₩104B-₩18.9B-₩13.6B-₩31.5B
Free cash flow-₩25.8B-₩10.9B-₩11.5B-₩14.8B-₩15.1B
Capital expenditure₩1.40B₩121M₩310M₩507M₩675M
Total debt₩1.29B₩1.19B₩51.1B₩21.6B₩17.8B

Quarterly statements and history in the cockpit →

Rznomics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%-20%-10%0%CADL456160688163EPRX68823868831765476998337867122509PRTA11676880981789603739000710IRLA2480300683476830.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Rznomics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×45616068816368823869982509PRTA476830.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rznomics is the large dot.

Rznomics competitors and peer comparison

How Rznomics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rznomics against its 20 peers (data as of 18 Nov 2026)
Measure476830.KSPeer medianRank in peer set
1-month return-19.7%-13.4%4th lowest of 21
6-month return-75.7%-22.0%lowest of 21
Distance from 52-week high-84.7%-41.5%2nd lowest of 21
Revenue growth (TTM)-65.4%+4.8%lowest of 16
Operating margin-1,111.6%-4.5%2nd lowest of 16
EV / Sales215.1×4.0×2nd most expensive of 16
ROIC minus cost of capital-155.3 pp-9.3 pp2nd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a

Questions

Which companies are Rznomics's closest peers?
The cockpit's peer set: Candel Therapeutics (CADL), G2GBIO (456160.KS), Shanghai Serum Bio-Technology (688163.SS), Eupraxia Pharmaceuticals (EPRX.TO), Shanghai Obio Technology (Group) (688238.SS), Shanghai ZJ Bio-Tech (688317.SS), Medigen Vaccine Biologics (6547.TWO), Edding Genor (6998.HK).
Is Rznomics expensive compared with its peers?
On ev / sales it trades at 215.1× against a peer median of 4.0×, 2nd most expensive of 16 in its peer set.
How has Rznomics stock performed?
Over six months to 18 Nov 2026 the shares returned -75.7% against -22.0% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.